Clinical Effectiveness of the Modified Release Trimetazidine in Microvascular Angina

Галин, П Ю; Губанова, Т. Г.

doi:10.15829/1560-4071-2016-12-84-89

Cited by 3 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The galvanizing was carried out according to the procedure in ref. [1] at 450°C for 3 hours using a saturating powder mixture containing zinc particles with a nanostructured oxide on the surface [3]. The coating thickness was determined using a magnetic thickness gauge.…”

Section: Methodsmentioning

confidence: 99%

“…A coating of typical thickness (10-60 μm) contains predominantly δ phase with a thin layer of Γ at the coating-steel interface. Special powders for thermal diffusion galvanizing, developed by the author [3], consisting of zinc particles coated with nanostructured zinc oxide [4], significantly improve the efficiency and controllability of the process.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Archives of Metallurgy and Materials

Biryukov¹,

Galin²,

Zakharyevich³

et al. 2019

View full text Add to dashboard Cite

A LAYER-BY-LAYER ANALYSIS OF THE CORROSION PROPERTIES OF DIFFUSION ZINC COATINGSTo obtain anti-corrosive thermo-diffusion zinc coatings, the authors use highly effective zinc saturating mixtures. This technology makes it possible to obtain coatings with a high zinc content in the δ-phase as well as a zinc-rich phase of FeZn 13 (ζ-phase) on the coating surface. As a result of long-term studies into the corrosion properties of thermo-diffusion zinc (TDZ) coatings conducted by the authors, a number of features of their corrosive behavior have been established. The corrosion rate of those coatings in desalted and chloride-containing media is lower than those of galvanic or hot-dip zinc coatings. The corrosion behavior depends on the content of zinc on the surface and the texture features of the coating. The results showed that on the surface of thermo-diffusion coatings in the corrosion on media containing chloride ions, zinc hydroxychloride (simonkolleite -Zn 5 Cl 2 [OH] 8 [H 2 O]) has been formed. Compared to coatings obtained by other methods, the rate of simonkolleite formation was higher on TDZ coatings, which might have a positive effect on their resistance in aggressive atmospheres.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Archives of Metallurgy and Materials

Biryukov¹,

Galin²,

Zakharyevich³

et al. 2019

View full text Add to dashboard Cite

show abstract

Personalized trimetazidine prescription as a cytoprotective agent in patients with coronary artery disease

Ромащенко

2021

Russ J Cardiol

View full text Add to dashboard Cite

Aim. To develop a personalized approach to the trimetazidine use in patients with coronary artery disease (CAD) based on the criteria for predicting the cytoprotective activity tested in vitro.Material and methods. We examined 30 patients with class I-III stable effort angina with concomitant hypertension and heart failure. The patients underwent echocardiography, complete blood count, biochemical tests with determination of the lipid profile, creatine phosphokinase (CPK), CPK-MB, renal and hepatic parameters. To determine the cytoprotective activity of trimetazidine, white blood cells (WBCs) of patients were examined in vitro using an Eclipse Ti-U inverted fluorescence microscope (Nikon, Japan). Living and dead cells were determined by staining WBCs with fluorescent dyes (Calcein AM, Ethidium bromide). Cell viability index (CVI) was calculated. The statistical processing was carried out. The criteria for predicting the trimetazidine cytoprotective effect were determined using Wald statistics.Results. When trimetazidine was injected into a WBC suspension sample, two types of cell viability changes were observed: in 60% of patients, CVI increased, on average, by 37% (from 23% to 60%, p<0,001) and in 40% of patients, CVI decreased, on average, by 30% (from 54% to 24%, p<0,05).A number of conditions of the patient initial status were identified for the manifestation of trimetazidine cytoprotective activity: grade 1 hypertension; right ventricular end diastolic dimension up to 30 mm according to echocardiography; normal lipid profile with a total cholesterol <5,3 mmol/L, very-low-density lipoproteins <1 mmol/L and an atherogenic coefficient up to 3 CU, myocyte and cardiomyocyte destruction (total CPK >100 U/L and CPK-MB >15 U/L), normal liver function (alanine aminotransferase <25 U/L), renal dysfunction (total protein <75 g/L, urea >8 mmol/L and blood creatinine >100 pmol/L), normal thrombopoiesis (immature platelet fraction <5%) and the state of functional adaptive system resistance (blood lymphocytes <30% and neutrophils >4x109/L).Conclusion. According to this in vitro analysis, the trimetazidine significantly increases (by an average of 37%) the cell (WBC) viability in 60% of patients with CAD. There are conditions of patient initial status, which specifies an individual pharmacodynamic target for the cytoprotective action of the drug.

show abstract

Evaluation of the efficiency of combined pharmacotherapy with the use of trimetazidine with prolonged release in patients with stable angina in outpatient practice

Luneva

Поветкин

2019

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Objective. To evaluate the effectiveness of complex pharmacotherapy with the inclusion in the treatment regimen of trimetazidine with a prolonged release in patients with stable angina. Materials and methods. The pilot study included 22 patients aged 45-75 years with combined cardiovascular pathology. In addition to the received therapy, all patients were prescribed the original trimetazidine with a prolonged release at a dose of 80 mg/day (Preductal® OD, Servier, Russia). The observation period was 2 months. The survey included the double implementation of the following methods: the number of strokes per week, the frequency of use of short - acting nitrates per week, blood pressure, heart rate, echocardiography, daily ECG monitoring, assessment of the quality of life (questionnaire SF-36, questionnaire of patients with stable angina SAQ). Results and discussion. When assessing the effect of ongoing pharmacotherapy on clinical and echoCG indicators in patients of the study group, significant positive dynamics was registered in the form of reducing the number of angina attacks and the number of short - acting nitrates used per week, a slight positive dynamics of EF on echoCG, episodes of pain and painless ischemia were eliminated according to the results of Holter monitoring), a significant positive dynamics of quality of life indicators was noted. Conclusion. Combined pharmacotherapy of patients with stable exertional angina with the inclusion of the trimetazidine with a prolonged release at a dose of 80 mg/day (Predductal® OD, Servier, Russia) has a significant positive pharmacodynamic effect in the form of an increase in the antianginal effect, improvement of Holter monitoring indicators and quality of patients life.

show abstract

Clinical Effectiveness of the Modified Release Trimetazidine in Microvascular Angina

Cited by 3 publications

References 4 publications

Archives of Metallurgy and Materials

Archives of Metallurgy and Materials

Personalized trimetazidine prescription as a cytoprotective agent in patients with coronary artery disease

Evaluation of the efficiency of combined pharmacotherapy with the use of trimetazidine with prolonged release in patients with stable angina in outpatient practice

Contact Info

Product

Resources

About